strong perform key product emerg market biosimilar
maintain buy rate upgrad tp
previous tp base forward price-to-earnings
multipl estim non-gaap ep
provid upsid potenti
estim revenu growth
estim base follow factor strong
growth major brand includ ibranc eliqui xtandi
xeljanz strong growth emerg market advanc
deliv solid perform quarter
growth revenu growth adjust ep
total revenu adjust ep
ep
growth due strong perform key brand
eliqui ibranc xeljanz well biosimilar emerg
ih revenu increas oper due
continu growth key brand includ eliqui ibranc
xeljanz global prevnar emerg market
 well xtandi
global ibranc revenu increas
oper due strong growth
intern develop market emerg market
xtandi allianc revenu grew
receiv fda approv supplementari new drug
applic xtandi base result phase
compani name inc tickerpfestock ratingbuyunchangedindustri viewoverweightpositivepric sept week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc septemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
xeljanz revenu increas oper
may fda approv xeljanz treatment
adult moder sever activ ulcer coliti
june european commiss approv xeljanz
combin methotrex treatment activ
psoriat arthriti adult patient
growth emerg market growth oper
growth biosimilar china led
way grow oper growth biosimilar
due inflectra certain channel well
busi science-bas innov
medicin busi includ biosimilar new
hospit busi unit anti-infect steril
inject patent brand generic-establish
medicin busi oper substanti autonomi
current price-to-earnings ratio
price-to-earnings volatil past three
year due volatil stock price price-to-earnings even
fallen stdev
averag price-to-earnings expect forward
price-to-earnings
expect revenu tax
rate expect adjust ep
expect
recommend buy rate stock tp
base perform develop
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date aug last split factor new per last split date jul inform pfizer inc septemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg interest income- incom special interest expense- minor incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc septemb
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr total prefer stock common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item pfizer inc septemb
provid oper activ increas compar
net cash gener reflect time receipt custom payment vendor
ordinari cours busi well decreas benefit plan contribut
provid invest activ increas compar
increas due increas net proce gener sale invest
cash need decreas cash use acquisit
use financ activ compar increas
due issuanc long-term debt correspond issuanc debt
higher purchas common stock
depreciation- defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end inc septemb
pfizer perform driven continu growth key brand
biosimilar emerg market key brand led growth
eliqui ibranc xeljanz
pfizer revenu increas compar
reflect favor impact foreign exchang
oper increas
total revenu declin compar
total intern revenu increas
compar
emerg market revenu increas compar
oper increas emerg market driven
eh segment primarili legaci establish product portfolio
well prevenar ih segment
increas
compar
sale increas
compar
sale increas compar
adjust cost sale increas
compar sale total revenu
compar total revenu sale
revenu increas compar
increas due
unfavor impact foreign exchang
unfavor impact hedg activ inter-company inventori
increas sale volum sever key product within product portfolio
increas royalti expens base mix product sold
non-recurr partial revers charg relat product
recal
si expens increas compar
adjust si expens increas
compar si expens total revenu
compar increas due invest
sever key product china increas also due unfavor
impact foreign exchang
 expens increas compar
adjust expens increas
compar expens total revenu
compar total revenu increas
due increas cost associ product pipelin
amort intang asset declin
compar amort intang asset
revenu declin compar
effect tax rate compar
adjust tax rate compar tax
rate impact decemb enact tax cut job
net incom increas compar
net margin compar
adjust incom increas compar
gaap ep increas compar
non-gaap ep increas compar
compar
gaap ep increas
compar
increas
compar
total revenu increas compar
total revenu decreas
compar total intern revenu increas
compar
emerg market revenu increas compar
oper increas emerg market driven
eh segment primarili legaci establish product portfolio well
prevenar ih segment
sale increas compar
adjust cost sale increas compar
sale revenu increas
compar sale revenu increas
compar
increas cost sale due
unfavor impact foreign exchang
unfavor impact hedg activ inter-company inventori
increas sale volum sever key product within product portfolio
increas royalti expens base mix product sold
si expens increas compar
adjust si expens increas
compar si expens total revenu
compar
increas si expens due invest sever key product
china increas also due unfavor impact foreign
exchang special one-tim bonu virtual
colleagu exclud execut
revenu increas
compar
compar
 expens increas compar
adjust expens increas
compar
 expens total revenu compar
total revenu increas due increas cost
associ product pipelin
amort intang asset flat compar
amort intang asset revenu
declin compar
effect tax rate compar
adjust effect tax rate compar
tax rate impact decemb enact tax cut
job act tcja
net incom increas compar
net margin compar gaap
ep increas compar
return directli sharehold
combin
dividend compos per share common stock
share repurchas compos open-market share
repurchas
acceler share repurchas agreement execut march
compar
net margin
compar
gaap
ep increas
compar
manag commerci oper two distinct busi
pfizer innov health ih pfizer essenti health eh
increas
compar
innov segment revenu increas
compar total revenu increas
compar
ih revenu increas oper due continu
growth key brand includ eliqui ibranc xeljanz global
prevnar emerg market well xtandi
total revenu ih segment increas
compar total intern revenu
increas compar
total revenu increas
compar total revenu increas
compar growth due
higher govern purchas pediatr indic certain
total revenu
ibranc increas
compar
total revenu increas compar
total intern revenu increas
compar
total revenu ibranc increas
compar total revenu increas
compar
total revenu
eliqui increas
compar
growth due uptak intern market mostli driven
key european market japan secur access
reimburs well ibranc class leadership among cyclin-depend
kinas inhibitor major market
total revenu increas compar
total intern revenu increas
compar
total revenu eliqui increas
compar total revenu increas
compar growth due
higher demand result increas market penetr novel oral
anticoagul market share gain
total revenu increas compar
total intern revenu increas
compar
total revenu
xeljanz increas
compar
total revenu xeljanz increas
compar total revenu increas
compar
growth due increas adopt among
rheumatologist grow awar among patient improv
payer access oper growth intern due
continu uptak emerg market japan canada well new
total revenu form increas compar
total intern revenu increas
compar
total revenu lyrica increas
compar total revenu increas
compar
growth due sustain demand posit price impact
 continu momentum lyrica japan partial off-set
loss exclus australia juli south korea august
total revenu increas compar
total intern revenu increas
compar
total revenu enbrel decreas
compar total revenu decreas
compar declin due
on-going biosimilar competit develop europ market
total revenu xtandi increas
compar total revenu increas
compar growth
due continu growth xtandi metastat castration-resist
total revenu
enbrel decreas
compar
total revenu
xtandi increas
compar
total revenu essenti health segment decreas
compar total revenu decreas
compar
total revenu decreas compar
total intern revenu increas
compar
eh revenu declin oper neg impact
oper declin legaci establish product portfolio
oper declin steril inject pharmaceut
portfolio develop market due continu legaci hospira product
shortag
oper declin peri-lo product portfolio
develop market due expect declin lyrica develop
europ partial off-set addit viagra revenu
canada previous record ih busi
eh revenu partial off-set
oper growth emerg market reflect growth across
oper growth biosimilar primarili inflectra
certain channel well develop europ
total revenu lyrica decreas
compar total revenu decreas
compar declin due
loss exclus develop europ market
total revenu
decreas
compar
total revenu
lyrica decreas
compar
decreas
compar
total viagra revenu report eh total revenu
decreas compar
total revenu decreas compar
total revenu decreas compar
viagra lost exclus decemb
total intern revenu increas
compar increas due increas
demand china russia partial off-set lower volum certain
middl eastern market latin america
total revenu inflectra increas
compar total revenu increas
compar
growth due continu uptak certain channel
well develop market europ partial off-set price pressur
market
total revenu increas compar
total intern revenu increas
compar
total revenu
inflectra increas
compar
product pipelin develop
bavencio avelumab talazoparib
juli first patient enrol phase javelin ovarian
parp trial evalu avelumab combin talazoparib patient
previous untreat advanc ovarian cancer trial explor
potenti novel combin avelumab develop
part allianc merck kgaa darmstadt germani
june announc receipt overal surviv os result
phase trial evalu ibranc combin
fulvestr compar placebo plu fulvestr women
metastat breast cancer whose diseas progress
prior endocrin therapi
result demonstr posit trend hazard ratio favor
ibranc combin although trend reach statist
signific os secondari endpoint trial
trial design optim detect statist signific
differ os
may announc posit top-lin result phase studi
examin use lyrica oral solut cv adjunct therapi
partial onset seizur pediatr epilepsi patient one month less
four year age result show adjunct treatment lyrica
mg/kg/day result statist signific reduct seizur
frequenc versu placebo primari efficaci endpoint
treatment lyrica lower dose mg/kg/day result
statist signific reduct seizur frequenc versu placebo
studi post-market requir fda
announc receipt
result phase
line result phase
studi examin use
lyrica oral solut cv
adjunct therapi
product pipelin develop
lyrica approv adjunct therapi partial onset seizur
pediatr epilepsi patient one month less four year age
complet studi result expect submit public
peer-review medic journal fda pediatr exclus
juli announc fda approv nivestym biosimilar
filgrastim elig indic refer
may announc result studi analyz real-world
effect data found prevnar reduc risk
hospit vaccine-typ pneumococc community-acquir
pneumonia ci adult age older
prevnar work real-world condit peopl receiv
pneumococc vaccin advis health care provid
mani underli medic condit increas risk
may announc fda approv retacrit
biosimilar epogen procrit epoetin indic
refer product enter agreement vifor
pharma inc commerci retacrit certain channel
announc result
found prevnar
reduc risk
hospit
pneumonia
ci adult
age older
product pipelin develop
may announc fda grant breakthrough
therapi design tafamidi treatment patient
transthyretin cardiomyopathi ttr-cm rare fatal underdiagnos
condit associ progress heart failur
decis support top-line result phase ttr-cm studi
attr-act tafamidi demonstr statist signific
reduct combin all-caus mortal frequenc
current approv pharmacolog treatment specif
indic diseas averag life expect peopl
ttr-cm year diagnosi
fda breakthrough therapi design intend expedit
develop review medicin intend treat seriou
life-threaten diseas preliminari clinic evid indic
drug may demonstr substanti improv exist therapi
may announc fda grant breakthrough
therapi design xalkori treatment patient
metastat non-smal cell lung cancer nsclc exon alter
diseas progress platinum-bas chemotherapi
fda also grant breakthrough therapi design xalkori
treatment patient relaps refractori system anaplast larg
cell lymphoma anaplast lymphoma kinas -posit
announc fda
therapi design
announc fda
therapi design
product pipelin develop
june announc european commiss ec
approv xeljanz mg twice daili bid combin methotrex
treatment activ psoriat arthriti adult patient
inadequ respons intoler prior disease-
control investig studi evalu efficaci safeti xeljanz
mg bid compar placebo adult patient activ ankylos
spondyl studi conduct adult patient
inadequ respons intoler nonsteroid
anti-inflammatori drug therapi xeljanz approv treatment
market
may committe medicin product human use chmp
european medicin agenc ema adopt posit opinion
recommend market author xeljanz treatment
adult patient moder sever activ ulcer coliti uc
chmp opinion review ec author
approv medic european union eu
may announc fda approv xeljanz mg bid
least eight week follow xeljanz mg bid mg bid
treatment adult patient moder sever activ uc
juli astella pharma inc astella announc
fda approv supplement new drug applic xtandi fda
action broaden indic xtandi men castration-resist
prostat cancer includ men non-metastat
approv make xtandi first oral medic fda-approv
nonmetastat metastat crpc
announc
juli
fda approv
applic xtandi
juli
spark announc
lead-in studi evalu
efficaci safeti
therapi usual care
product pipelin develop
comprehens updat develop pipelin includ overview
research list compound develop target
indic phase develop well mechan action
candid phase candid phase registr
june announc os data archer trial
evalu dacomitinib first-lin treatment patient local
advanc metastat nsclc egfr-activ mutat compar
trial show median os month patient receiv
dacomitinib ci repres seven-month
improv compar month gefitinib ci
os data archer present oral present
annual meet american societi clinic oncolog
publish simultan journal clinic oncolog
juli spark announc
initi phase openlabel multi-cent lead-in studi evalu
efficaci safeti current factor ix prophylaxi replac therapi
may spark announc cumul follow-up
patient year observ week
particip on-going phase clinic trial investig
sever moder sever percent hemophilia
discontinu routin infus factor ix concentr annual bleed
rate particip reduc annual infus
rate reduc none particip experienc seriou
advers event thrombot event factor ix inhibitor
may data cutoff
product pipelin develop
june announc fda accept compani new
drug applic nda grant prioriti review statu glasdegib
pdufa goal date decis fda decemb
juli fda notifi review period nda
lorlatinib extend three month allow time review
addit inform recent submit respons fda
submiss addit inform determin fda
constitut major amend nda result extens
pdufa goal date three month august novemb
achiev proof-of-concept next
recently-complet phase trial demonstr vaccin
candid safe well-toler induc function immun
respons could kill twenti serotyp
develop potenti extend coverag beyond
thirteen serotyp cover prevnar includ seven addit
serotyp preval caus pneumococc diseas adult children
current plan phase program
announc fda
accept compani
nda grant
prioriti review statu
concept pf-
product pipelin develop
juli updat estim complet date
rivipansel evalu safeti efficaci time discharg reset phase
trial investig canada continu enrol sickl cell
diseas scd patient studi complet expect
studi previous expect complet late
updat calcul base histor enrol last
june announc fda accept file grant
prioriti review statu compani nda talazoparib
pdufa goal date decis fda decemb
ema also accept market author applic
talazoparib patient popul
juli compani lilli announc
week phase studi patient osteoarthr oa pain evalu
subcutan administr tanezumab investig human
monoclon antibodi met three co-primari endpoint
studi demonstr patient receiv two dose
tanezumab separ eight week experienc statist signific
improv pain physic function patient overal assess
oa compar receiv placebo
preliminari safeti data show tanezumab gener well
toler patient discontinu treatment due advers
event rapidli progress oa observ tanezumab-tr patient
frequenc less observ placebo arm
event osteonecrosi observ trial
updat estim
complet date
safeti efficaci time
discharg reset
juli
compani
lilli announc
phase studi
patient
administr
tanezumab met three
product pipelin develop
juli announc european commiss
approv trazimera biosimilar herceptin treatment
overexpress breast cancer overexpress metastat gastric
gastroesophag junction adenocarcinoma approv follow
recommend chmp may
juli announc increas commit
manufactur invest build one
world portag michigan
 invest strengthen capabl produc suppli
critic life-sav inject medicin patient around world
known modular asept process new multi-stori
square-footage product facil also support area economi
creat estim new job next sever year
expand pfizer presenc portag locat kalamazoo counti
compani employ peopl one largest
juli announc organ compani three
science-bas innov medicin busi includ
current innov health busi unit except consum
healthcar well biosimilar new hospit medicin busi
unit commerci pfizer global portfolio steril inject
anti-infect medicin
off-pat brand gener establish medicin busi
oper substanti autonomi within pfizer
consum healthcar busi continu evalu
strateg altern decis expect
announc
increas commit
 manufactur
invest build one
technic
product facil
world portag
product pipelin develop
chang effect begin compani fiscal
year provid financi report reflect reorgan
begin issuanc first-quart earn
june fda inform complet evalu
correct action close februari warn letter issu
mcpherson kansa manufactur facil determin
address violat contain warn letter futur
fda inspect regulatori activ assess adequaci
sustain correct site remain voluntari action
june announc plan invest
biotechnolog emerg growth compani pfizer
ventur addit increas fund extend leadership
ventur capit investor expand team leverag expertis
across ventur capit invest busi develop drug discoveri
announc plan
invest
biotechnolog
compani
guidanc conclus
adjust sale revenu
effect tax rate adjust incom
incom
revenu expect
tax rate expect
adjust ep expect
deliv strong result due strong growth brand
eliqui ibranc xeljanz well biosimilar emerg market
total revenu increas adjust ep increas
ep
ih revenu increas oper due continu growth
key brand essenti health segment saw strong oper
growth emerg market growth oper
growth biosimilar
return directli sharehold dividend share
repurchas demonstr continu commit return capit
sharehold continu advanc pipelin believ
largest promis array late-stag prospect
look ahead sever potenti near-term opportun core therapeut
area continu see potenti approv
potenti blockbust
adjust ep
continu
advanc pipelin
believ
largest
promis array late-
non- reconcili
non- reconcili
non- reconcili
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi compar
revenu growth ttm basi compar
net margin ttm basi compar
ep growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc septemb
mrqgross mrqcog mrqsg mrqr mrqoper mrqnet margin pfizer inc septemb
invest flow
sale
mrqfinanci mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn asset pfizer inc septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer annual itemsquarterli item pfizer inc septemb
balanc item
outstand equival market debt common prefer purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free inc septemb
current price-to-earnings ratio price-to-earnings volatil past
three year due volatil stock price price-to-earnings even fallen stdev
averag price-to-earnings expect forward price-to-earnings
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdershar report outvalueblackrock vanguard group inc america jp morgan northern trust wellington manag compani geod capit manag price row associ top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut ishar vanguard/windsor fidel select sector spdr fund-health vanguard -valu mf seri trust i-mf valu competit
developmentspf grant fda breakthrough therapi design pneumococc conjug vaccin prevent diseas pneumonia adult age year olderseptemb inc pneumococc conjug vaccin candid receiv breakthrough therapi design drug administr fda prevent invas diseas pneumonia caus streptococcu pneumonia serotyp vaccin adult age year older expect start phase trial month pfizer present posit phase data alopecia areata late-break session european academi dermatolog venereolog eadv congressseptemb inc result phase studi oral janu kinas jak inhibitor tyrosin kinas tyk inhibitor compar placebo patient moder sever alopecia areata aa autoimmun diseas character hair loss often associ profound psycholog consequ jak inhibitor met primari efficaci endpoint improv hair regrowth scalp rel baselin week point point respect measur sever alopecia tool score point scale tafamidi phase transthyretin amyloid cardiomyopathi attr-act studi result present late-break data esc congress inc primari result tafamidi phase transthyretin cardiomyopathi attr-act studi show tafamidi significantli reduc hierarch combin all-caus mortal frequenc cardiovascular-rel hospit compar placebo period patient wild-typ variant hereditari transthyretin amyloid cardiomyopathi rare fatal underdiagnos condit associ progress heart failur approv pharmacolog treatment fda approv biosimilar nivestym filgrastim-aafi juli inc unit state food drug administr fda approv nivestym filgrastim-aafi biosimilar elig indic refer product fda approv base review comprehens data packag total evid demonstr high degre similar nivestym compar refer product inc septemb
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc septemb
consensu view analyst trend stock
forward price-to-earnings
compar
well
valuat comparisonpfeindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim inc septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price show upward trend quarter surg
stock gave return period averag trade volum share last
stock price volatil year show upward trend sinc june
stock gave return past rang stock
stock price show upward trend past given return past
growth stock price due strong perform
deliv strong quarterli result growth revenu increas adjust
ep growth due key brand like ibranc eliqui xeljanz also due
growth emerg market biosimlar maintain buy rate stock tp
expect revenu grow
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
